LSD Has the Smallest Patent Pipeline, While Definium Leads Trials With Only One Granted Patent

LSD has the smallest active patent pipeline in Altitude's tracker, with 14 granted and 34 pending applications, because its core composition of matter has been open prior art since Sandoz's patents expired by 1963. Companies can therefore claim only narrower inventions such as salts, formulations, delivery methods, prodrugs, or analytical techniques. Compass Pathfinder has the largest combined LSD-linked total, although its claims overlap with psilocybin; Basel and Terran hold broader multi-compound portfolios, while Roche's expired or expiring patents concern LSD detection rather than treatment. The central outlier is Definium Therapeutics, whose DT120 program has reported positive Phase 3 results and FDA Breakthrough Therapy designation for generalized anxiety disorder, yet has just one granted US patent and 18 pending applications. The comparison suggests that late-stage clinical evidence and regulatory exclusivity may matter more than issued patent depth near approval. DT120 is not FDA-approved, and the discussion is business and regulatory reporting, not medical advice.